Table 1.
Genomic feature ranks. Entries present the rank position followed by the feature type: copy number variation (C), expression (E), mutation from the oncomap platform (Mo), and mutation from hybrid capture sequencing (Mh). Missing entries (−) represent features that had ranks higher than 1,000, were not represented in the data, or were filtered-out from the analysis.
| CCLE | Sanger | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Drug | Gold | Stream | Ridge | Lasso | Elastic-net | Stream | Ridge | Lasso | Elastic-net |
| 17-AGG | NQO1 | 2-E | 2-E | 1-E | 2-E | 1-E | 1-E | 1-E | 1-E |
|
| |||||||||
| AZD-0530 | EGFR | 1-Mo | 1-Mo | 1-Mo | 1-Mo | - | - | - | - |
|
| |||||||||
| Erlotinib | EGFR | 1-Mo | 1-Mo | 1-Mo | 1-Mo | - | - | 863-E | - |
| 10-Mh | 9-Mh | 73-Mh | 38-Mh | - | - | - | - | ||
| 36-C | 39-C | 347-E | 258-C | - | - | - | - | ||
|
| |||||||||
| Lapatinib | ERBB2 | 8-E | 8-E | 1-E | 5-E | 6-E | 2-E | 1-E | 2-E |
| 1-C | 1-C | 2-C | 2-C | - | - | - | - | ||
|
| |||||||||
| PD-325901 | BRAF | 94-Mo | 67-Mo | 191-Mo | 235-Mo | 3-Mo | 1-Mo | 2-Mo | 1-Mo |
| 2-Mh | 2-Mh | 3-Mh | 3-Mh | 180-E | 181-E | 252-E | 214-E | ||
|
| |||||||||
| PF-2341066 | MET | 9-C | 3-C | 19-C | 45-C | - | - | - | - |
| HGF | 3-E | 1-E | 1-E | 7-E | - | - | - | - | |
|
| |||||||||
| PHA-665752 | MET | - | - | - | - | - | - | - | - |
| HGF | 104-E | 212-E | 540-E | 480-E | - | - | - | - | |
|
| |||||||||
| PLX4720 | BRAF | 1-Mo | 1-Mo | 1-Mo | 1-Mo | 1-Mo | 1-Mo | 1-Mo | 1-Mo |
| 2-Mh | 2-Mh | 6-Mh | 3-Mh | - | - | - | - | ||